Aethlon Medical’s (AEMD) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $7.00 price target on the medical equipment provider’s stock. HC Wainwright also issued estimates for Aethlon Medical’s Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.73) EPS and FY2026 earnings at ($0.49) EPS.

Separately, StockNews.com raised shares of Aethlon Medical to a “sell” rating in a research report on Wednesday.

Aethlon Medical Price Performance

Shares of Aethlon Medical stock opened at $0.58 on Wednesday. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.85. The firm’s 50-day moving average is $0.65 and its two-hundred day moving average is $0.49. The stock has a market cap of $8.44 million, a price-to-earnings ratio of -0.37 and a beta of 1.88.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.09. On average, equities analysts expect that Aethlon Medical will post -0.82 earnings per share for the current year.

Institutional Trading of Aethlon Medical

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at approximately $25,000. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at approximately $26,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at approximately $31,000. Virtu Financial LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at approximately $81,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at approximately $186,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.